Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer

Seminars in Oncology

Volumn 26, Issue 4 SUPPL. 12, 1999, Pages 78-83

  Baselga, J ^a   Tripathy, D ^a   Mendelsohn, J ^a   Baughman, S ^a   Benz, C C ^a   Dantis, L ^a   Sklarin, N T ^a   Seidman, A D ^a   Hudis, C A ^a   Moore, J ^a   Rosen, P P ^a   Twaddell, T ^a   Henderson, I C ^a   Norton, L ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GROWTH INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT TRANSFORMATION; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTO ONCOGENE; TUMOR GROWTH;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 0032823487     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)